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2Abstract
The Global Asthma Network (GAN), established in 2012, followed the International Study of
Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700,000
adolescents and children from 156 centres in 56 countries; it found marked worldwide
variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the
current understanding of these diseases; ISAAC Phase Three involved over 1,187,496
adolescents and children (237 centres in 98 countries). It found that asthma symptom
prevalence was increasing in many locations especially in low- and middle-income countries
where severity was also high, and identified several environmental factors that required
further investigation.
GAN Phase I, described in this article, builds on the ISAAC findings by collecting further
information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma
emergency room visits, hospital admissions, management and use of asthma essential
medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first
global monitoring of asthma in children and adults since 2003, further evidence will be
obtained to understand asthma, management practices and risk factors, leading to further
recognition that asthma is an important non-communicable disease and to reduce its global
burden.
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Short Sentence
The Global Asthma Network undertakes global studies of asthma surveillance, management
and risk factors
3Introduction
An estimated 241 million people in all parts of the world suffer from asthma1, and nearly 1000
people per day die from asthma2. The Global Asthma Network3 (GAN), was established in
2012, to improve asthma care globally, with a focus on low- and middle-income countries
(LMICs), through enhanced surveillance, research collaboration, capacity building and access
to quality-assured, affordable, essential asthma medicines. GAN was formed by scientists from
the International Study of Asthma and Allergies in childhood (ISAAC) 1991-2012 (Phases
One4, Two5 and Three6) and from the International Union Against Tuberculosis and Lung
Disease (The Union) following production of the first Global Asthma Report (GAR) 20117,
launched in New York in 2011 at the time of the United Nations High-Level meeting on non-
communicable diseases (NCDs). A second GAR8, written and produced by GAN in 2014 was
launched in October at the 45th Union World Conference on Lung Health, Barcelona, Spain.
These reports highlight the existing evidence of the burden of asthma, provide evidence-based
recommendations for cost-effective health improvement, especially in LMICs, and advocate
for increasing the priority given to interventions for asthma.
ISAAC Phase One (1994-1995) identified large variations in the prevalence of symptoms of
asthma, rhinitis and eczema, with differences of between 20 fold and 60 fold between centres,
showing marked differences in asthma prevalence in populations with similar genetic or ethnic
backgrounds9, suggesting that environmental risk factors in the broadest sense were the major
determinants of the prevalence of asthma in a community. ISAAC Phase Three (2001-2003)
examined time trends and included new questions on risk factors which identified many
environmental associations10. These were the last ISAAC studies.
The Union implemented asthma pilot projects in Benin11, China (Huaiyuan County)12, El
Salvador13and Sudan14. These projects found that inhaled corticosteroids were not available in
any of these sites in the public sector, and that asthma was greatly underdiagnosed. The Union’s
Asthma Drug Facility enabled countries to purchase quality–assured essential affordable
asthma medicines, and inhaled corticosteroids became widely used resulting in a reduction in
hospitalisations15, 16.
GAN Phase I is a development from ISAAC (particularly Phases One17-21and Three22-24), and
The Union11, 12, 14, 25. GAN Phase I has extended its surveillance to include adults, for whom
there are limited global data, and to assess asthma management, which is commonly suboptimal
in settings with limited access to quality-assured essential asthma medicines.
GAN aims to progress recommendations in the GARs and produce a further report in 2018
engaging and reinforcing the role of Government’s health ministers, the World Health
Organisation (WHO), policy-makers, health-workers, those with asthma, development
partners/donors and media, in efforts to improve asthma care globally. GANs core activities
are global surveillance of asthma prevalence, severity, management, and risk factors;
promotion of standard case management of asthma; operational research; capacity building;
engagement with policy makers; and access to affordable quality-assured essential medicines.
The four main hypotheses of GAN Phase I are: (i) globally, the burden of asthma is changing
in adults and children; (ii) there is large variation in the diagnosis of asthma; (iii) in many
locations, asthma is under-diagnosed and its management is suboptimal; (iv) and that there are
potentially remedial risk factors of asthma.
4Methodology
Study subjects
Each GAN centre is a defined geographical area. Within each centre subjects will be selected
in the same manner as ISAAC Phase Three. The same age groups will be used: 13/14 year
old adolescents (self-completed questionnaires) and 6/7 year old children (parental completed
questionnaires), and GAN Phase I adds their parents as an adult group (see next paragraph).
The sampling unit will be a school for each age group which will be selected using a table of
random numbers. A minimum of 10 schools will be required in each centre, or all schools in
the sampling frame if there are fewer than 10 schools. Students of both age groups are
selected either by grade/level/year or by age group.
Additionally, GAN is recommending that the parents/guardians of the adolescents and
children are also surveyed in order to obtain symptom prevalence of asthma, rhinitis and
eczema as there has been a paucity of international prevalence data on adult asthma. The
GAR 2011 and GAR 2014 reported data on asthma in adults mainly from the World Health
Survey 2003, which had small numbers of participants in most countries and which was a
general health survey with very limited information specifically on asthma and wheeze. In
addition the adults in GAN will provide more in-depth environmental data, particularly from
the parents of the adolescent group, as the adolescents may not be able to answer some
questions relating to their early life.
Study Design
GAN Phase I is a cross-sectional, multi-centre, multi-country, epidemiological research,
study design. This will meet these objectives of GAN Phase I (i) to conduct asthma
surveillance around the world in 2 age groups of children, and their parents, measuring
prevalence, severity, management and risk factors, using similar methods to ISAAC Phase
Three (ii) to examine time trends in prevalence, severity and risk factors from centres
participating in ISAAC Phase Three (iii) to evaluate the appropriateness of asthma
management, especially access to quality-assured essential asthma medicines, as defined by
WHO.
Methods
The methodology will be the same as ISAAC Phase Three methodology, with expansion, in
particular, in the areas of on risk factor determinants and on management of asthma. The
manual containing the information required to undertake the fieldwork is available from the
GAN website3. Each centre has a defined geographical area and the centres that undertook
ISAAC Phase Three and/or Phase One are expected to use the same sampling frame so that
comparisons of data can be subsequently undertaken. As in ISAAC, new centres are
encouraged to join to obtain wider diverse global participation and to encourage rural/urban
comparisons. Principal Investigators (PIs) are identified at the registration stage which began
in November 2015. Phase I will be co-ordinated by Professor Neil Pearce, London School of
Hygiene & Tropical Medicine, London, UK who will lead the main data centre. Professor
Luis García-Marcos, IMIB Bioresearch Institute and University of Murcia, Spain will lead
the data centre for Spanish and Portuguese language centres. The GAN Global Centre, will be
led by Professor Innes Asher, the University of Auckland, Auckland, New Zealand, assisted
by Philippa Ellwood, the GAN Research Manager.
An Expression of Interest form was available from 2012, from the GAN website until formal
registrations opened on 1st November 2015. As of 1 July 2016 there are expressions of
interest from 344 centres in 132 countries with formal registrations from 89 centres in 35
countries. The registration document identifies PIs (two may be appointed per centre, one for
5adolescents and children and the other for the adult group) and a National Coordinator may
be appointed if there is more than one centre in a country and if there is an identified need.
The manual contains all the necessary information needed to undertake the fieldwork and
describes the criteria required for inclusion in the worldwide data set.
The same standardised written core questionnaires, developed for ISAAC for use in Phases
One and Three, will be used in GAN. Demographic questions include the participant’s name,
where allowed, age, date of birth, school (for the adolescents and children), gender, and date
of interview. Questionnaires will be coded using a unique number for each centre, school
and participant to ensure confidentiality and to link the questionnaires between the adults
adolecents and children. Collection of data regarding participants ethnicity is optional in
which case ethnic categories from local census forms should be used26.
The written core questionnaires, that were used in ISAAC, have had a question about doctor-
diagnosed asthma, rhinitis and eczema added. The core questions are both sensitive and
specific, have good content, construct and concurrent and predictive validity27. Height and
weight measurements will be taken by the fieldworkers in schools. The environmental risk
factor questionnaire, developed for ISAAC Phase Three has been expanded for use in GAN.
Not all of these questions are compulsory as indicated in the GAN Manual. Some questions
that were not considered appropriate for the adolescent group to complete in ISAAC Phase
Three have been included in the adult questionnaire. The adult symptoms questionnaire was
derived from elements from ISAAC and the European Community Respiratory Health
Survey (ECRHS) with the aim of capturing the spectrum of chest symptoms that might be
attributable to asthma in young and middle-aged adults and the diagnostic labels applied (see
supplementary files).
As in ISAAC, a video asthma questionnaire will be an optional tool - the international version
as used in ISAAC28. This 6 minute non-verbal video shows clinical signs of asthma
symptoms and was developed by the Wellington Asthma Research Group, to avoid problems
of translation and comprehension of terms such as ‘wheeze’ or ‘whistling’ and their use in
culturally heterogeneous populations29. The video has the advantage of obtaining data from a
large number of students quickly and efficiently.
Sample size and subjects
As in ISAAC, a sample size of 3000 participants per age group (and therefore potentially
6000 adults of each group) will be used. The sample size will provide greater than 99% (at
the 1% level of significance) to detect differences in the prevalence of wheezing of 30% in
one centre and 25% in another centre27. As sampling is done by school, while the information
is gained from the school pupils and adults, there is likely to be a cluster effect. Like ISAAC
the analysis will incorporate adjustment for cluster sampling using the design effect30, which
is important for large studies where clusters of different size may be used in different regions.
If centres are unable to obtain 3000 participants, provided they do not have less than 1000 per
age group and fulfil the criteria described in the GAN manual, they may be included.
The mean participation in ISAAC Phase Three was 88% in adolescents and 84.5% in
children. High participation is sought for GAN Phase I - at least 80% for 13/14 year olds and
70% for 6/7 year olds and 70% for adults/parents. For the adolescent group a return visit to
school can be made to capture the absentees and for the children redistribution of
6Analyses
On-line documents for data entry are available from the GAN website. Once the centres have
registered, PIs are emailed a personalised copy of the centre report for use during fieldwork.
The centre report can be completed on-line and submitted via the website to the GAN Global
centre in Auckland, New Zealand.
At the time of conducting the survey, fieldworkers are requested to check the questionnaires
for any obvious demographic entry errors so that this information can be corrected using
school records. No alteration to the symptom and risk factor questionnaire data is allowed.
Data is entered onto the computer as it is presented on the questionnaire, preserving
confidentiality by coding. At least 10% of the data must be double entered to identify data
entry errors. Centre PIs are responsible for their own data coding and entry. An epi info
package is available on the GAN website for investigators to use. Centres may wish to use
questionnaire scanning software such as OMR (Optical Mark Recognition) for data entry,
however procedures to deal with data entry errors must be documented and sent to the GAN
Global Centre. The software should have the ability to export the data set as a .CSV file.
Data will be submitted to the GAN Global Centre, Auckland, New Zealand, at the same time
the centre report is submitted. The GAN Global Centre will acknowledge receipt of the data
and centre report, will undertake some quality control checks and will then send the data to
one of two designated data centres. The data centre in Murcia, led by Professor Luis García-
Marcos will undertake the data checks on all Spanish and Portuguese speaking centres. The
data centre in London, led by Professor Neil Pearce will undertake the data checks for centres
using all other languages.
The approach to data analyses will be similar to that used in ISAAC6. This standardised
approach is particularly important for examination of time trends in prevalence and severity
from ISAAC to GAN31, 32, to ensure comparability. For the environmental questions, the
approach used will follow that of ISAAC33, and assessment of time trends in risk factors will
allow changes in asthma prevalence to be analysed in relation to changes in prevalence of
established risk factors within the centres which participated in ISAAC Phase Three.
On completion of the data checks and methodology checks from the centre report any
deviations from protocol will be examined carefully by the GAN Steering Group. Provided the
deviation from protocol is not severe enough for exclusion of the centre, the data will be
included in the analyses and subsequent publications. Protocol variations that are accepted will
be footnoted in the tables of the publications. This follows the same principles as adopted in
ISAAC Phases One and Three.
Ownership of data, ethics, dissemination of results and funding
Each centre owns its own data and is free to publish this data without prior approval of the
GAN Steering Group. All worldwide publications will have a writing group ‘and the Global
Asthma Network Phase I Study Group’. This group, comprising all Steering Group members,
National Coordinators (if one has been appointed) and Principal Investigators of centres
included in the paper, will be named in each paper and consulted on the paper in preparation
prior to journal submission. Each centre is required to obtain ethics approval from their local
ethics committee prior to the start of their study. Each centre is required to provide funding
for the fieldwork.
Piloting of GAN Phase I
The pilot of the GAN methodology and questionnaires for the adolescent group, the children
and the parents/adults of both groups was undertaken in one school for each age group in
7Auckland, New Zealand, Cartagena, Spain and Madani in east-central Sudan]. The
adolescents completed the questionnaire at school and gave immediate feedback which
enabled some question formats to be improved. The questions were discussed with the
students, for example, if they found the questions on smoking intrusive. Most participants
were appreciative of the anonymity of questionnaires, although some found it a bit long. For
the children and for the parent/adults of both groups, the questionnaires were sent home for
completion and return (for the parent/adults, this was a new methodology). Investigators are
encouraged to include the parent/adult group as the information provided will give new
information on adults, and additional useful family history.
Significance of GAN
GAN will expand on the ISAAC Phase Three time trends findings to explore in depth the
negative and positive associations found with the environmental risk factor data. In addition,
this will be the first major global surveillance of asthma prevalence, severity, management
and risk factors which includes adults/parents of two age groups of school children. GAN
will also collect further information on the topics addressed in the Global Asthma Reports
2011 and 2014: including asthma prevalence and severity; diagnosis of asthma; unplanned
visits including emergency room visits and hospital admissions; management policies; and
access to quality-assured essential asthma medicines. New centres from countries that had not
previously undertaken ISAAC will provide rich new information.
GAN Phase I will build on the findings of ISAAC by collecting further information on asthma,
rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital
admissions, management and use of quality-assured essential asthma medicines. The subjects
will be the same age groups as ISAAC Phase Three, and their parents. In this first global
monitoring of asthma in children and adults since 2003, further evidence will be obtained to
understand asthma, management practices and risk factors, leading to further recognition of
asthma as an important non-communicable disease and to reduce its global burden.
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